In-Depth Examination Of 10 Analyst Recommendations For Moderna
Portfolio Pulse from Benzinga Insights
10 analysts have provided varied opinions on Moderna (NASDAQ:MRNA) over the past quarter, with ratings ranging from bullish to bearish. The average 12-month price target has increased by 4.01% to $147.3. Analysts have maintained, raised, or announced new ratings and price targets, reflecting their evolving perceptions of Moderna's market standing. Despite challenges in revenue growth, net margin, ROE, and ROA, Moderna's debt management remains conservative.
June 27, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed views on Moderna, with a 4.01% increase in the average 12-month price target to $147.3. Despite challenges in revenue growth, net margin, ROE, and ROA, the company's debt management remains conservative.
The mixed analyst ratings and the slight increase in the average price target suggest a neutral short-term impact on Moderna's stock. While there are significant challenges in revenue growth and profitability, the conservative debt management provides some stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100